{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:24Z","timestamp":1790717064473,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nanjing Second Hospital Talent Promotion Project","award":["RCMS232013"],"award-info":[{"award-number":["RCMS232013"]}]},{"name":"Key Project of Research Project of Jiangsu Provincial Health Commission","award":["K2023018"],"award-info":[{"award-number":["K2023018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31265-x","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T11:33:36Z","timestamp":1765020816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TRIP13 alters mitochondrial function and promotes bortezomib resistance in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yule","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoda","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"31265_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5 (2021).","journal-title":"Lancet"},{"key":"31265_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 11, 40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4 (2021).","journal-title":"Blood Cancer J."},{"key":"31265_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu, Q., Yang, D., Li, H., Niu, T. & Tong, A. Multiple myeloma: signaling pathways and targeted therapy. Mol. Biomed. 5, 25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w (2024).","journal-title":"Mol. Biomed."},{"key":"31265_CR4","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.gendis.2023.06.037","volume":"11","author":"X Zhou","year":"2024","unstructured":"Zhou, X., Xu, R., Wu, Y., Zhou, L. & Xiang, T. The role of proteasomes in tumorigenesis. Genes Dis. 11, 101070. https:\/\/doi.org\/10.1016\/j.gendis.2023.06.037 (2024).","journal-title":"Genes Dis."},{"key":"31265_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ajco.13459","volume":"17","author":"Y Bai","year":"2021","unstructured":"Bai, Y. & Su, X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac. J. Clin. Oncol. 17, 29\u201335. https:\/\/doi.org\/10.1111\/ajco.13459 (2021).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"31265_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020532","author":"L Haertle","year":"2023","unstructured":"Haertle, L. et al. Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15020532 (2023).","journal-title":"Cancers (Basel)"},{"key":"31265_CR7","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1111\/cas.14154","volume":"110","author":"N Nishimura","year":"2019","unstructured":"Nishimura, N. et al. Novel p97\/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. Cancer Sci. 110, 3275\u20133287. https:\/\/doi.org\/10.1111\/cas.14154 (2019).","journal-title":"Cancer Sci."},{"key":"31265_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.csbj.2019.06.005","volume":"17","author":"S Lu","year":"2019","unstructured":"Lu, S., Qian, J., Guo, M., Gu, C. & Yang, Y. Insights into a crucial role of TRIP13 in human cancer. Comput. Struct. Biotechnol. J. 17, 854\u2013861. https:\/\/doi.org\/10.1016\/j.csbj.2019.06.005 (2019).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"31265_CR9","doi-asserted-by":"publisher","first-page":"12019","DOI":"10.1073\/pnas.1412901111","volume":"111","author":"E Eytan","year":"2014","unstructured":"Eytan, E. et al. Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc. Natl. Acad. Sci. USA 111, 12019\u201312024. https:\/\/doi.org\/10.1073\/pnas.1412901111 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31265_CR10","doi-asserted-by":"publisher","first-page":"26718","DOI":"10.18632\/oncotarget.14957","volume":"8","author":"Y Tao","year":"2017","unstructured":"Tao, Y. et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget 8, 26718\u201326731. https:\/\/doi.org\/10.18632\/oncotarget.14957 (2017).","journal-title":"Oncotarget"},{"key":"31265_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/0008-5472.can-18-3987","volume":"80","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Huang, J. & Li, B. A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Blood Cancer J. 80, 536\u2013548. https:\/\/doi.org\/10.1158\/0008-5472.can-18-3987 (2020).","journal-title":"Blood Cancer J."},{"key":"31265_CR12","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1007\/s00432-023-04672-8","volume":"149","author":"Y Cui","year":"2023","unstructured":"Cui, Y., Wang, F. & Fang, B. Mitochondrial dysfunction and drug targets in multiple myeloma. J. Cancer Res. Clin. Oncol. 149, 8007\u20138016. https:\/\/doi.org\/10.1007\/s00432-023-04672-8 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"31265_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood-2021-153744","volume":"138","author":"A Sharma","year":"2021","unstructured":"Sharma, A. et al. Mitochondrial electron transport chain inhibition promotes resistance to proteasome inhibitors in multiple myeloma. Blood 138, 1611\u20131611. https:\/\/doi.org\/10.1182\/blood-2021-153744 (2021).","journal-title":"Blood"},{"key":"31265_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050696","author":"D Tibullo","year":"2020","unstructured":"Tibullo, D. et al. Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells. Biomolecules https:\/\/doi.org\/10.3390\/biom10050696 (2020).","journal-title":"Biomolecules"},{"key":"31265_CR15","doi-asserted-by":"publisher","first-page":"177572","DOI":"10.1016\/j.ejphar.2025.177572","volume":"996","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Acevaltrate overcomes myeloma resistance to bortezomib via pyroptosis by promoting BAX translocalization to mitochondria. Eur. J. Pharmacol. 996, 177572. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177572 (2025).","journal-title":"Eur. J. Pharmacol."},{"key":"31265_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","volume":"104","author":"M Ri","year":"2016","unstructured":"Ri, M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int. J. Hematol. 104, 273\u2013280. https:\/\/doi.org\/10.1007\/s12185-016-2016-0 (2016).","journal-title":"Int. J. Hematol."},{"key":"31265_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/carcin\/bgac071","volume":"43","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma. Carcinogenesis 43, 1030\u20131038. https:\/\/doi.org\/10.1093\/carcin\/bgac071 (2022).","journal-title":"Carcinogenesis"},{"key":"31265_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ijc.28149","volume":"133","author":"IS Song","year":"2013","unstructured":"Song, I. S. et al. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int. J. Cancer 133, 1357\u20131367. https:\/\/doi.org\/10.1002\/ijc.28149 (2013).","journal-title":"Int. J. Cancer"},{"key":"31265_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4161\/cc.4.2.1414","volume":"4","author":"PG Richardson","year":"2005","unstructured":"Richardson, P. G., Mitsiades, C., Hideshima, T. & Anderson, K. C. Proteasome inhibition in the treatment of cancer. Cell Cycle 4, 290\u2013296 (2005).","journal-title":"Cell Cycle"},{"key":"31265_CR20","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907\u20134916. https:\/\/doi.org\/10.1182\/blood-2005-08-3531 (2006).","journal-title":"Blood"},{"key":"31265_CR21","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530\u20131534. https:\/\/doi.org\/10.1182\/blood-2002-08-2543 (2003).","journal-title":"Blood"},{"key":"31265_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbcan.2011.10.003","volume":"1825","author":"S Frankland-Searby","year":"2012","unstructured":"Frankland-Searby, S. & Bhaumik, S. R. The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta 1825, 64\u201376. https:\/\/doi.org\/10.1016\/j.bbcan.2011.10.003 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"31265_CR23","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans, R. et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489\u20132499. https:\/\/doi.org\/10.1182\/blood-2007-08-104950 (2008).","journal-title":"Blood"},{"key":"31265_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072201","author":"C Leonardo-Sousa","year":"2022","unstructured":"Leonardo-Sousa, C. et al. Revisiting Proteasome inhibitors: Molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance. Molecules https:\/\/doi.org\/10.3390\/molecules27072201 (2022).","journal-title":"Molecules"},{"key":"31265_CR25","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8639","author":"L Zhao","year":"2023","unstructured":"Zhao, L., Ye, S., Jing, S., Gao, Y. J. & He, T. Targeting TRIP13 for overcoming anticancer drug resistance (review). Oncol. Rep. https:\/\/doi.org\/10.3892\/or.2023.8639 (2023).","journal-title":"Oncol. Rep."},{"key":"31265_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/0008-5472.CAN-18-3987","volume":"80","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 80, 536\u2013548. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3987 (2020).","journal-title":"Cancer Res."},{"key":"31265_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3324\/haematol.2023.282789","volume":"109","author":"G Chen","year":"2024","unstructured":"Chen, G. et al. Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma. Haematologica 109, 1206\u20131219. https:\/\/doi.org\/10.3324\/haematol.2023.282789 (2024).","journal-title":"Haematologica"},{"key":"31265_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2024512118","author":"W Xie","year":"2021","unstructured":"Xie, W. et al. Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2024512118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31265_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1152\/physrev.00041.2020","volume":"102","author":"JF Garbincius","year":"2022","unstructured":"Garbincius, J. F. & Elrod, J. W. Mitochondrial calcium exchange in physiology and disease. Physiol. Rev. 102, 893\u2013992. https:\/\/doi.org\/10.1152\/physrev.00041.2020 (2022).","journal-title":"Physiol. Rev."},{"key":"31265_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12964-024-01628-4","volume":"22","author":"T Li","year":"2024","unstructured":"Li, T. et al. NCX1\/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway. Cell Commun Signal 22, 258. https:\/\/doi.org\/10.1186\/s12964-024-01628-4 (2024).","journal-title":"Cell Commun Signal"},{"key":"31265_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal, E. A. et al. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 5, 7. https:\/\/doi.org\/10.1186\/s40170-017-0169-9 (2017).","journal-title":"Cancer Metab."},{"key":"31265_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/d1mo00106j","volume":"18","author":"EA Zaal","year":"2022","unstructured":"Zaal, E. A. et al. Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Mol. Omics 18, 19\u201330. https:\/\/doi.org\/10.1039\/d1mo00106j (2022).","journal-title":"Mol. Omics"},{"key":"31265_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/ol.2022.13228","volume":"23","author":"L Meng","year":"2022","unstructured":"Meng, L., Gu, G. & Bi, L. Transient receptor potential channels in multiple myeloma. Oncol. Lett. 23, 108. https:\/\/doi.org\/10.3892\/ol.2022.13228 (2022).","journal-title":"Oncol. Lett."}],"updated-by":[{"DOI":"10.1038\/s41598-026-41220-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31265-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:28:36Z","timestamp":1773757716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31265-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31265"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31265-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-41220-z","URL":"https:\/\/doi.org\/10.1038\/s41598-026-41220-z","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of Nanjing Second Hospital (No. 2023-LS-ky-052).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"1426"}}